Latest Information Update: 08 Feb 2008
At a glance
- Originator AstraZeneca
- Mechanism of Action Prostaglandin E1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Pain in United Kingdom (unspecified route)
- 08 Feb 2008 Discontinued - Preclinical for Pain in USA (unspecified route)
- 21 Dec 1999 Preclinical development for Pain in United Kingdom (Unknown route)